Shareholders who lost money in shares of Picard Medical, Inc. (NYSE: PMI) should contact Wolf Haldenstein immediately

Shareholders of Picard Medical, Inc. (NYSE: PMI) who have experienced financial losses due to their investments are urged to reach out to Wolf Haldenstein Adler Freeman & Herz LLP without delay. The law firm has recently initiated a class action lawsuit targeting Picard Medical, covering all individuals and entities that purchased Picard shares between September 2, 2025, and October 31, 2025. Investors must move quickly, as the deadline to apply for lead plaintiff status is set for April 3, 2026.

The complaint claims that the company and its affiliates engaged in a fraudulent stock promotion scheme, which involved the dissemination of false information via social media and impersonation of financial professionals. Furthermore, it alleges that insiders may have used offshore or nominee accounts to execute the coordinated sale of shares during a campaign designed to artificially inflate share prices. The lawsuit also highlights that Picard's public statements and risk disclosures did not adequately address the misinformation and abnormal trading activity purportedly influencing the stock's value.

Wolf Haldenstein, established in 1888, carries an extensive history of advocating for investors affected by financial misrepresentation. With over 125 years of expertise in securities litigation, the firm is committed to ensuring that investors’ rights are upheld. Shareholders who believe they may have a claim or who have information that could assist in the investigation are encouraged to get in touch with the firm directly.

Those interested in joining the case can contact Wolf Haldenstein at 1-800-575-0735 or email classmember@whafh.com. Detailed information about the firm and case can be found on their official website.

Investors who have faced losses in Picard Medical, Inc. (NYSE: PMI) shares should promptly consider reaching out to Wolf Haldenstein Adler Freeman & Herz LLP, especially in light of the recent class action lawsuit filed against the company. This case indicates that significant concerns surround its past activities, particularly related to misleading statements and a potential fraudulent stock promotion scheme.

During the defined Class Period of September 2, 2025, to October 31, 2025, allegations surfaced that Picard Medical may have engaged in practices that artificially inflated stock prices through misleading information disseminated via social media and impersonated financial professionals. Such actions could have severely impacted shareholders, confusing both potential and current investors about the true state of the company.

For those shareholders who lost money during this timeframe, this situation represents not only a loss but also an opportunity to seek recourse. Wolf Haldenstein has a long-standing reputation for advocating for investors. With over 125 years of experience in securities litigation, the firm is well-equipped to navigate the complexities of such cases, ensuring investors' rights are robustly defended.

The deadline for shareholders to express their intent to participate in the lawsuit as lead plaintiffs is April 3, 2026. Acting quickly is critical; investors may be able to recover some of their lost funds which could mitigate the financial damage suffered during the alleged fraudulent activity.

In light of the serious allegations against Picard Medical, shareholders are encouraged to act quickly by contacting Wolf Haldenstein through their office numbers or email. It’s crucial to remain engaged and informed, as collective action may enhance the likelihood of a favorable outcome for those impacted.